Answers are grounded in this paper and cite their sources.
Menin inhibitors have emerged as effective targeted therapies for acute leukemias with KMT2A rearrangements and NPM1 mutations. By disrupting the menin-KMT2A interaction, these agents suppress canonical menin-dependent leukemogenic transcriptional programs. However, primary resistance and relapse remain major clinical challenges. Acquired MEN1 mutations cause on-target resistance by impairing inhibitor binding while preserving menin-KMT2A function. Increasing clinical and experimental evidence indicates that suppression of canonical menin targets does not invariably result in leukemia control. Non- MEN1 resistance can involve failure to establish stable transcriptional repression, persistence of noncanonical menin-regulated transcription, impaired growth-arrest or apoptotic responses, and broader epigenomic or lineage-state adaptation. These findings support a multistep model in which target engagement, canonical transcriptional suppression, stable repression, and downstream cell-fate responses make distinct contributions to leukemia control. We review these emerging mechanisms and highlight the need to define their prevalence and clinical relevance through longitudinal studies of patients before treatment, during response, and at resistance.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: